2 options
Clinical aspects of psychopharmacology in childhood and adolescence / Donald E. Greydanus ... [et al.], editors.
- Format:
- Book
- Series:
- Health and human development series.
- Health and human development book series
- Language:
- English
- Subjects (All):
- Pediatric psychopharmacology.
- Adolescent psychopharmacology.
- Physical Description:
- 1 online resource (280 p.)
- Edition:
- 1st ed.
- Place of Publication:
- Hauppauge, NY : Nova Science, c2011.
- Language Note:
- English
- Summary:
- A large proportion of children and youth have mental health problems that follow different trajectories over time. Adolescence is a period in which latent mental problems emerge, with as many as one third of adolescents presenting with complaints significant enough to warrant a visit to the doctor. Since the mid-1950s, a considerable number of psychoactive medications have been developed, with primarily adults with mental health disorders being the main focus. Only a proportion of these drugs were subsequently studied in children and adolescents in well-designed, controlled trials with a sufficiently long-term follow-up. This means that the treatment decision of the prescribing physician carries a unique burden of personal responsibility. This book presents the psychopharmacologic agents that are available for children and adolescents, as well as the side effects, drug interactions, and the indicated monitoring parameters of these medications.
- Contents:
- Intro
- CLINICAL ASPECTS OF PSYCHOPHARMACOLOGY IN CHILDHOOD AND ADOLESCENCE
- Contents
- Foreword
- Introduction: pediatric psychopharmacology
- Modern psychopharmacology
- Conclusions
- References
- Section One: ADHD
- Chapter I Attention deficit hyperactivity disorder: pharmacologic management in children and adolescents
- Introduction
- Assessment and treatment principles
- Diagnostic criteria
- Diagnostic work up
- Comorbidity
- Discussing medications and monitoring with patients and caretakers
- Treatment planning and multimodal options
- Psychopharmacology of ADHD
- FDA approved stimulants
- Methylphenidate (MPH) preparations
- Oral short acting MPH formulations (3 - 5 hours duration)
- Multimodal treatment study of children with ADHD (MTA) study
- Preschool ADHD treatment study (pats)
- Other MPH IR formulations
- Oral intermediate acting MPH formulations (up to 8 hours duration)
- Long acting MPH formulations (up to 12 hours duration)
- MPH transdermal formulation (MTS)
- Amphetamine (AMP) preparations
- Short acting AMP formulations (up to 6 hours)
- Long acting AMP formulations (up to 8-10hHrs)
- Prodrug formulation
- Special safety considerations regarding stimulants
- Cardiovascular
- Growth
- Abuse potential
- Tics
- FDA approved non stimulants
- Atomoxetine (strattera)
- Guanfacine XRr (intuniv)
- Non FDA approved treatments
- Monitoring tools
- ADHD pharmacotherapy FaQs
- Acknowledgments
- Chapter II Attention deficit hyperactivity disorder and comorbid substance abuse
- Epidemiology
- Patterns of prescription stimulant medications
- Can childhood ADHD contribute to adolescent substance abuse?
- Detecting comorbid ADHD and SUD
- Clinical considerations.
- Minimizing risks
- Impact of treatment on course of sud
- ADHD medications with low abuse potential
- Behavioral treatments
- Clinical management
- Section Two: Mental Health Aspects
- Chapter III Psychotherapy in the age of pharmacology
- A literature review
- Pharmacotherapy
- Psychotherapy
- Chapter IV Child and adolescent depression
- Clinical features
- Comorbid conditions
- Treatment
- Chapter V Pediatric bipolar disorder
- Medication management
- Acute-phase treatment
- Maintenance treatment
- Treatment of comorbid disorders
- Conclusion
- Chapter VI Anxiety disorders in children and adolescents
- Selective serotonin re-uptake inhibitorsc (SSRIs)
- SSRI adverse effects
- Serotonin and nor-epinephrine re-uptake inhibitors
- Benzodiazepines
- Tricyclic antidepressants
- Buspirone
- Beta-blockers
- Hydroxyzine
- Mirtazepine and nefazodone
- Chapter VII Oppositional defiant and conduct disorders
- Non-medication treatments
- Medication treatments
- Psychostimulants
- Atomoxetine
- Lithium
- Atypical antipsychotics (AAs)
- Non-lithium mood stabilizers
- Other medications
- Chapter VIII Aggressive and violent behavior
- Rule-out medical disorders
- Rule-out substance use disorders (SUDs)
- Identify psychiatric disorders
- Disruptive behavior disorders (DBDs).
- Mood disorders
- Anxiety disorders
- Psychotic disorders
- Impulse control disorders
- Tic disorders
- Personality disorders
- Chapter IX Tic disorders in children and adolescents
- Definitions
- Differential diagnosis/comorbidity
- Psychopharmacology of tic disorders
- Alpha agonists
- Antipsychotics
- Dopamine receptor agonists
- Baclofen
- Stimulants
- Antidepressants
- Anticonvulsants
- Others
- Section Three: Specific Disorders
- Chapter X Autistic spectrum disorders
- Etiology
- Assessment
- Chapter XI Schizophrenia in children and adolescents
- Important considerations while diagnosing childhood schizophrenia
- Rating and diagnostic scales
- Psychopharmacology
- Atypical antipsychotics
- Clozapine
- Typical Antipsychotics
- Depot injections of medication
- Psychosocial interventions
- Chapter XII Cognitive-adaptive disabilities
- Mood disorders
- Attention-deficit/hyperactivity disorder (ADHD)
- Other disorders
- Bipolar disorder
- Attention-deficit/hyperactivity disorder
- Section Four: Other Use
- Chapter XIII Substance abuse disorders in adolescents: pharmacologic management
- Alcohol
- Drug interactions
- Amphetamines
- Cocaine
- Opioids
- Heroin dependence management
- References.
- Chapter XIV Smoking cessation and pharmacological agents
- Nicotine replacement therapy
- Nicotine inhaler
- Nicotine gum
- Nicotine lozenge
- Nicotine nasal spray
- Nicotine patch
- Bupropion SR
- Varenicline
- Second-line medications
- Clonidine
- Nortriptyline
- Chapter XV Sleep disorders in children and adolescents
- Evaluation
- Insomnia
- Excessive daytime sleepiness
- Narcolepsy
- Klein-levin syndrome
- Parasomnias
- Restless legs syndrome (RLS)
- Sleep disordered breathing
- Section Five: Conclusions
- Chapter XVI Pediatric psychopharmacology: where do we go from here?
- Pediatric psychopharmacology: quo vadis?
- Benefit of psychopharmacologic versus psychological therapies
- Benefit of psychopharmacology in pediatric mental illness
- Hope versushHype of pharmaceutical companies' for-profit research
- Intervention of governments in research
- Impact of genetics on psychopharmacology
- Results of sleep research on pediatric mental health
- Training of primary care clinicians in mental health
- Section Six: Acknowledgments
- Chapter XVII About the editors
- Chapter XVIII About the Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, MSU/Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States
- Mission and service
- Research activities
- Chapter XIX About the National Institute of Child Health and Human Development in Israel
- Mission
- Service and academic activities
- National collaboration
- International collaboration
- Targets
- Chapter XX About the book series "Health and human development".
- Clinical aspects of psychopharmacology in childhood and adolescence
- Index
- Blank Page.
- Notes:
- Description based upon print version of record.
- Includes bibliographical references and index.
- ISBN:
- 1-61122-715-1
- OCLC:
- 836864168
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.